Sangui Biotech International (HAM:SBH) Valuation Rank

View and export this data going back to 2000. Start your Free Trial

What is Sangui Biotech International Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Sangui Biotech International Valuation Rank Related Terms

Thank you for viewing the detailed overview of Sangui Biotech International's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Sangui Biotech International Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sangui Biotech International Inc (HAM:SBH) » Definitions » Valuation Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

Bleichenbrucke 9, Hamburg, DEU, 20354

Website

http://www.sanguibiotech.com

Sangui Biotech International Inc develops pharmaceutical, medical and cosmetic products, through its subsidiary. The company develops oxygen carriers for providing oxygen transport in humans due to acute or chronic lack of oxygen and in the case of chronic wounds. It has also developed external applications of oxygen transporters in the form of sprays for healing chronic wounds and gels and emulsions for the regeneration of the skin. The products offered are artificial oxygen carriers; Chitoskin wound pads; and haemoglobin-based wound spray technology sold under the brand name Granulox. It derives revenue from licensing fees on sales of its wound spray product.